Assessment of socio-economic availability of spironolactone diuretics (C03DA01) and furosemide (C03CA01) of the domestic pharmaceutical market

Authors

  • I. O. Fedyak Ivano-Frankivsk National Medical University, Ukraine
  • O. V. Maksymenko Ivano-Frankivsk National Medical University, Ukraine

DOI:

https://doi.org/10.24959/sphhcj.19.140

Keywords:

marketing analysis, monthly market monitoring, diuretics of the spironolactone group (C03DA01) and furosemide (C03CA01), cirrhosis, ascites

Abstract

The results of market monitoring of diuretics recommended for the treatment of liver cirrhosis complications have been analyzed in the article. From 01/01/2017 till 31/12/2018 a monthly monitoring of the physical and socio-economic availability for domestic patients with ascites was performed.

Aim. To interpret the dynamics of data of the marketing analysis of medicines recommended for the treatment of patients with liver cirrhosis and its most common complication – ascites.

Materials and methods. Marketing analysis carried out by the method of monthly monitoring of the range, average wholesale and selling prices, indicators of socio-economic availability (price liquidity ratios, adequacy of solvency of the population, , availability (D) of medicines) according to the data “The software complex “Apteka” resource (http://pharmbase.com.ua/) for the period of 01.01.2017-31.12.2018.

Results. It has been found out that diuretics of spironolactone (C03DA01) and furosemide (C03CA01) groups are sufficiently represented at the domestic pharmaceutical market; their socio-economic availability has shown a positive dynamics. Among the medicines of spironolactone the lowest wholesale and retail price was for Spironolacton-Darnitsa, PrAS FF “Darnitsa”, while the highest price was for Veroshpiron, Gedeon Richter; among the medicines of furosemide – for Furosemid, LTD RP “GNSSLS” and Lazyx, “Sanofi India Limited”, respectively. A sharp reduction in prices for some drugs was due to the inclusion of active substances in the Government program “Available medicines”, and the period of decline in cost coincided with the time of their introduction into the Register of Medicines, which cost was subjected to compensation. As for range in prices, they were due to the fluctuation of the hryvnia against the dollar in 2017-2018.

Conclusions. The assessment of the social-economic availability of diuretics of the spironolactone and furosemide groups by monitoring of the liquidity ratios (Cliq), adequacy of the population’s solvency (Сa.s), availability (D) of medicines allows them to be considered financially affordable for an average inhabitant suffering from ascites because of liver cirrhosis. The market window for the future domestic medicine based on the combination of spironolactone and furosemide (100 mg + 40 mg, respectively) has been identified, it is expected to have a price advantage over the imported analog.

References

Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) tretynnoi (vysokospetsializovannoi) medychnoi dopomohy “Tsyroz pechinky ta yoho uskladnennia” (proekt). (2016). Available at: http://old.moz.gov.ua/ua/print/dn_20160803_0.html

Tsyroz pechinky ta yoho uskladnennia: klinichna nastanova (2017). Available at: http://mtd.dec.gov.ua/images/dodatki/KN/AKN_TSP.pdf

EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. (2010). Journal of Hepatology, 53 (3), 397–417. doi: 10.1016/j.jhep.2010.05.004.

Angeli, P., Fasolato, S., Mazza, E. et al. (2010).Combined versus sequential diuretic treatment of ascites in nonazotemic patients with cirrhosis: results of an open randomized clinical trial. Gut, 59 (1), 98–104. doi: 10.1136/gut.2008.176495.

Runyon, B. A. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis: Update 2012. (2012). Available at: https://www.aasld.org/sites/default/files/guideline_documents/141020_Guideline_Ascites_4UFb_2015.pdf

Nemchenko, A. S., Kosiachenko, K. L., Kovalenko, O. V., Kubarieva, I. V. (2011). Metodychni rekomendatsii z provedennia monitorynhu tsin na likarski zasoby, shcho zakupovuiutsia za derzhavnymy tsilovymy prohramamy. Kharkiv: Vyd–vo NFaU, 17.

Nemchenko, A. S., Kosiachenko, K. L., Nemchenko, O. A. (2012). Tsinoutvorennia na likarski zasoby. (2nd ed.). Kharkiv: FOP Vyrovets A. P.: Apostrof, 304.

Hermanok, T. A., Ivko, T. I. (2014). Metodolohiia marketynhovykh, farmakoepidemiolohichnykh ta farmakoekonomichnykh doslidzhen. Vinnytsia: Nilan–LTD, 64.

Tykhonov, O. I., Bohdan, N. S., Shpychak, O. S. (2016). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4, 78–89. doi: 10.24959/uekj.16.38.

Kotvitska, A. A. (2015). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 5, 41–46.

Slobodianiuk, M. M., Baihush, Yu. V. (2016). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 1, 72–79. doi: 10.24959/uekj.16.7.

Poluichak, N. Yu., Demchuk, M. B., Yur’ieva, O. O., Hroshovyi, T. A. (2015). Farmatsevtychnyi chasopys, 3, 34–39.

Iakovlieva, L. V., Portianka, M. M., Kyrychenko, O. M. (2016). Proceeding from Sotsialna farmatsiia: stan, problemy ta perspektyvy: materialy naukovoho sympoziumu u ramkakh VIII Natsionalnoho zizdu farmatsevtiv Ukrainy (15–16 veresnia 2016). (p. 141). Kharkiv.

Nemchenko, A. S., Kurylenko, Yu. Ye. (2018). Farmatsevtychnyi chasopys, 2, 77–81.

Nemchenko, A. S., Balynska, M. V. (2017). Sotsialna farmatsiia v okhoroni zdorov’ia, 3 (2), 70–79. doi: 10.24959/sphhcj.17.75.

Fediak, I. O., Bilyk, I. P. (2018). Sotsialna farmatsiia v okhoroni zdorov’ia, 4 (1), 72–82. doi: 10.24959/sphhcj.18.106.

Downloads

Published

2019-03-11

Issue

Vol. 5 No. 1 (2019)

Section

Health organization

License

Copyright (c) 2019 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).